



*vaccines*



an Open Access Journal by MDPI

## State-of-the-Art Vaccine Research in AustralAsia

Guest Editor:

**Dr. Mariusz Skwarczynski**

School of Chemistry and  
Molecular Biosciences, The  
University of Queensland, St  
Lucia, QLD 4072, Australia

Deadline for manuscript  
submissions:

**31 January 2025**

### Message from the Guest Editor

Asia and Australia are globally renowned for their research on vaccine development, which also includes extensive efforts toward the development of SARS-CoV-2 vaccines. Indeed, there is a large number of research teams devoting their work to vaccine development across Australasian countries. Moreover, many countries have their own medical research center/institute working on many aspects of vaccine development; these include the following, to mention a few: Eliza Hall Institute of Medical Research and Doherty Institute (Australia), Center for Vaccine and Adjuvant Research and Institute for Vaccine Research and Development (Japan), International Vaccine Institute (Korea), Beijing Institute of Biotechnology, Chinese PLA Center for Disease Control and Prevention, National Institute of Diagnostics and Vaccine Development in Infectious Diseases (China), and Malaysian Genome and Vaccine Institute (Malaysia).

This Special Issue is devoted to vaccine development in Australia and Asia. The Special Issue is expected to promote vaccine work from Australasia worldwide. Research articles and reviews are welcome, as long as they provide a consolidated view of the state of the art in this area.



[mdpi.com/si/132907](https://mdpi.com/si/132907)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)